Announcements & Circulars-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

Investors

Information Disclosure

Listing Documents

Financial Reports

Announcements & Circulars

Company Presentation

Corporate Governance

Stock Information

Corporate Communications

Email Subscription

Announcements & Circulars

The announcement begins in December 2019

VOLUNTARY ANNOUNCEMENT - IND APPROVAL BY NMPA FOR A PHASE IA/IB CLINICAL TRIAL OF JSKN003 FOR THE TREATMENT OF ADVANCED SOLID TUMORS 2022-10-27
GRANT OF AWARD SHARES UNDER THE RESTRICTED SHARE AWARD SCHEME 2022-10-24
GRANT OF SHARE OPTIONS 2022-10-24
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2022 2022-10-05
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN A PHASE I CLINICAL TRIAL OF JSKN003 (KN026-ADC) IN AUSTRALIA FOR THE TREATMENT OF ADVANCED SOLID TUMORS 2022-09-19
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2022 2022-09-06
VOLUNTARY ANNOUNCEMENT - UPDATES ON CLINICAL DATA OF KN046 AND KN026 FOR PRESENTATION AT ESMO CONGRESS 2022 2022-09-05
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2022 2022-08-31
Date of Board Meeting 2022-08-18
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN A PHASE II CLINICAL TRIAL OF KN046 COMBINED WITH AXITINIB FOR THE FIRST-LINE TREATMENT OF ADVANCED NSCLC 2022-08-08

10 11 12 13 14 15 16